Drug Trial Radar · NCT05707949
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
Last checked: Nov 20, 2026Latest source record: Aug 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
650
Planned (sponsor's estimate)
Start
Jun 5, 2023
Primary completion
Apr 2032
Study completion Apr 2032
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Feb 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. A number of treatments are available for adults with migraine but there are limited approved treatments available for participants less than 18 years of age. The main goal of the study is to evaluate the long-term safety and tolerability of atogepant in pediatric participants between the ages of 6 and 17 with migraine. Atogepant is a medicine currently approved to treat adults with migraine (0 to 14 migraine days per month) and is being studied in pediatric participants between the ages of 6 and 17 with a history of migraine. This is a Phase 3, open-label study of atogepant in participants with a history of migraine. Participants must have completed participation in another study of atogepant (lead-in study). Participants must have 4 to 14 migraine days and less than 15 headache days for episodic migraine, and \>= 15 headache days and \>= 8 migraine days for chronic migraine in the 4-week screening electronic diary (eDiary; similar to a smart phone). Around 650 participants will be enrolled in the study at approximately 100 sites worldwide. Atogepant is a tablet taken once a day by mouth. Participants between the ages of 12 and 17 will receive high dose atogepant for 52 Weeks. Participants between the ages of 6 and 11 will receive an atogepant dose determined in the lead-in study for 52 Weeks. There may be a bigger responsibility for participants in this study. Participants will attend regular visits during the study at a hospital or clinic. The effects of treatment will be checked by medical assessments, blood tests, checking for side effects, and completing questionnaires.
Conditions
- Migraine Prophylaxis
Interventions
AtogepantDrug
Oral Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Adverse Events (AEs)Time frame: Up to 56 Weeks
- Percentage of Participants with Potentially Clinically Significant Lab ValuesTime frame: Up to 52 Weeks
- Percentage of Participants with Potentially Clinically Significant Clinical 12-lead Electrocardiogram (ECG)Time frame: Up to 52 Weeks
- Percentage of Participants with Potentially Clinically Significant Vital Sign ParametersTime frame: Up to 52 Weeks
- Percentage of with Participants with Treatment-Emergent Suicidal Ideations with Intent, with or without a Plan (i.e., Type 4 or 5 on Columbia-Suicide Severity Rating Scale [C-SSRS]), or any Suicidal BehaviorsTime frame: Up to 52 Weeks
- Percentage of Participants with Change in Menstrual Cycle (Female Participants Only)Time frame: Up to 52 Weeks
- Change from Baseline in Tanner Staging ScoreTime frame: Baseline (Week 0) through Week 52
- Change from Baseline in Behavior Rating Inventory of Executive Function, 2nd Edition (BRIEF 2) questionnaireTime frame: Baseline (Week 0) through Week 52
Locations
86 sites in 16 countries. Site status is shown where the registry gives one.
Rehabilitation & Neurological Services /ID# 250910
Huntsville, Alabama
Preferred Research Partners /ID# 250937
Little Rock, Arkansas
Advanced Research Center /ID# 251616
Anaheim, California
Sunwise Clinical Research /ID# 250913
Lafayette, California
Alliance for Research Alliance for Wellness /ID# 250911
Long Beach, California
Excell Research, Inc /ID# 251611
Oceanside, California
Lumos Clinical Research Center /ID# 251608
San Jose, California
Advanced Neurosciences Research, LLC /ID# 250925
Fort Collins, Colorado
Northwest Florida Clinical Research Group, LLC /ID# 251614
Gulf Breeze, Florida
Advanced Research Institute of Miami /ID# 250916
Homestead, Florida
My Preferred Research LLC /ID# 250931
Miami, Florida
Asclepes Research Centers - Spring Hill /ID# 250912
Spring Hill, Florida
Coastal Georgia Child Neurology /ID# 250938
Brunswick, Georgia
Deaconess Clinic - Gateway Health Center /ID# 250923
Newburgh, Indiana
College Park Family Care Center Overland Park /ID# 251609
Overland Park, Kansas
Michigan Headache & Neurological Institute (MHNI) /ID# 250920
Ann Arbor, Michigan
Proven Endpoints LLC /ID# 258083
Ridgeland, Mississippi
Cognitive Clinical Trials (CCT) - Papillion /ID# 251610
Papillion, Nebraska
Goryeb Children's Hospital /ID# 250934
Morristown, New Jersey
Dent Neurosciences Research Center, Inc. /ID# 250915
Amherst, New York
Modern Migraine MD /ID# 258082
New York, New York
Headache Wellness Center /ID# 251612
Greensboro, North Carolina
Patient Priority Clinical Sites, LLC /ID# 250922
Cincinnati, Ohio
CincyScience /ID# 250935
West Chester, Ohio
Lynn Institute of Oklahoma City /ID# 250926
Oklahoma City, Oklahoma
Access Clinical Trials, Inc. /ID# 250914
Nashville, Tennessee
FutureSearch Trials of Neurology /ID# 251613
Austin, Texas
3A Research - East El Paso /ID# 250909
El Paso, Texas
Earle Research /ID# 250908
Friendswood, Texas
Family Psychiatry of The Woodlands /ID# 250936
The Woodlands, Texas
ClinPoint Trials /ID# 250942
Waxahachie, Texas
Pantheon Clinical Research /ID# 251615
Bountiful, Utah
Highland Clinical Research /ID# 250924
Salt Lake City, Utah
Office of Maria Ona /ID# 250939
Franklin, Virginia
Core Clinical Research /ID# 250932
Everett, Washington
AZ Sint-Jan Brugge /ID# 247527
Bruges, Belgium
Uza /Id# 247885
Edegem, Antwerpen, Belgium
Stollery Children's Hospital /ID# 251426
Edmonton, Alberta, Canada
Montreal Children's Hospital /ID# 250649
Montreal, Quebec, Canada
Herlev Hospital /ID# 247725
Herlev, Capital Region, Denmark
Showing 40 of 86 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.